This document discusses how the global healthcare profit pool will shift between 2010 and 2020. It predicts that the total profit pool will grow at 4% annually from $520 billion to $740 billion over this period. However, profitability will decline for most players as the sources of growth and margins change significantly between sectors and regions. Innovative pharmaceutical and medical technology companies will see much slower growth and declining margins. In contrast, providers of healthcare delivery and lower-margin sectors like generics will capture a larger share of profits. To remain competitive, companies will need to develop new business models focused on improving healthcare delivery and outcomes rather than just generating more products and procedures.
The document provides an overview of the Indian pharmaceutical industry. It notes that the industry is expected to grow to $100 billion by 2025, making India one of the top global markets. Currently valued at $27.57 billion, the industry is growing at 12.89% annually and exports over $16 billion worth of drugs globally each year. The generics market and biotech sector also have strong growth potential. The industry benefits from low production costs, a large skilled workforce, and government support for further development.
The document provides an overview of the pharmaceutical industry in India. Some key points:
- The Indian pharmaceutical industry is expected to grow to $55 billion by 2020, expanding at a CAGR of 12.89% from 2015-2020.
- India accounts for 20% of global exports in generics, with pharmaceutical exports at $16.84 billion in 2016-17, expected to reach $20 billion by 2020.
- The biotech industry in India is also growing rapidly, estimated to increase from $11 billion in 2015-16 to $100 billion by 2024-25.
IMS - Global Use of Medicines 2020 by Nitesh BheleNitesh Bhele
By 2020, global medicine use will reach 4.5 trillion doses, a 24% increase from 2015 levels. Over half of the world's population will consume over 1 dose per person per day, driven by increased access in large emerging markets like India, China, Brazil, and Indonesia. Developed markets will continue to use more branded and specialty medicines per capita, while emerging markets will see greater use of generics and over-the-counter drugs. New medicines introduced in the past 10 years will account for 0.1% of volumes in emerging markets versus 2-3% in developed markets.
Indian Pharma market is predominantly a branded generic market. How does this auger for the industry per se, how is it then placed to grow going in the future. This brief presentation attempts to throw some light on the said topic
The Indian pharmaceutical sector is estimated to reach $100 billion by 2025, accounting for 10% of the global pharmaceutical industry by volume. It currently accounts for 20% of global generic exports. The sector is expected to grow at a CAGR of 12.89% until 2020 to reach $55 billion. By 2020, India will be among the top 3 pharmaceutical markets by growth and 6th largest globally. The government has implemented policies and initiatives like 'PharmaVision 2020' to make India a global pharmaceutical leader and improve affordability and availability of medicines.
The document provides an overview of the pharmaceutical industry in India. Some key points:
- India is a major global player in pharmaceuticals, accounting for around 3% of the global industry. The market is expected to grow to $55 billion by 2020 and $100 billion by 2025.
- India has a large generics market and is a major exporter, accounting for 20% of global exports. Exports were $16.84 billion in 2016-17 and are projected to reach $20 billion by 2020.
- Key segments of the market include generics, Active Pharmaceutical Ingredients, Contract Research and Manufacturing Services, and biosimilars. Anti-infectives represent the largest segment dome
Indian pharmaceutical industry supplies over 50% of global demand for various vaccines and drugs. It is expected to grow at 22.4% annually to reach $55 billion by 2025. India accounts for 20% of global exports in generics. The domestic market is expected to reach $27.9 billion by 2020 with high potential for growth in generics. Increased investment in R&D and acquisitions are driving growth in the robust Indian pharmaceutical sector.
Indian pharmaceutical sector is estimated to account for 3.1-3.6% of the global pharmaceutical industry in value terms and 10% in volume terms. The country's pharmaceutical industry is expected to expand at a CAGR of 12.89% over 2015-2020 to reach US$ 55 billion. India accounts for 20% of global exports in generics. By 2020, India is likely to be among the top three pharmaceutical markets by incremental growth and 6th largest market globally in absolute size. The generics market stood at US$ 26.1 billion in 2016 and has high potential for growth. By 2024-25, India's biotech industry is estimated to increase to US$ 100 billion from US$ 11 billion in F
The document provides an overview of the Indian pharmaceutical industry. It notes that the industry is expected to grow to $100 billion by 2025, making India one of the top global markets. Currently valued at $27.57 billion, the industry is growing at 12.89% annually and exports over $16 billion worth of drugs globally each year. The generics market and biotech sector also have strong growth potential. The industry benefits from low production costs, a large skilled workforce, and government support for further development.
The document provides an overview of the pharmaceutical industry in India. Some key points:
- The Indian pharmaceutical industry is expected to grow to $55 billion by 2020, expanding at a CAGR of 12.89% from 2015-2020.
- India accounts for 20% of global exports in generics, with pharmaceutical exports at $16.84 billion in 2016-17, expected to reach $20 billion by 2020.
- The biotech industry in India is also growing rapidly, estimated to increase from $11 billion in 2015-16 to $100 billion by 2024-25.
IMS - Global Use of Medicines 2020 by Nitesh BheleNitesh Bhele
By 2020, global medicine use will reach 4.5 trillion doses, a 24% increase from 2015 levels. Over half of the world's population will consume over 1 dose per person per day, driven by increased access in large emerging markets like India, China, Brazil, and Indonesia. Developed markets will continue to use more branded and specialty medicines per capita, while emerging markets will see greater use of generics and over-the-counter drugs. New medicines introduced in the past 10 years will account for 0.1% of volumes in emerging markets versus 2-3% in developed markets.
Indian Pharma market is predominantly a branded generic market. How does this auger for the industry per se, how is it then placed to grow going in the future. This brief presentation attempts to throw some light on the said topic
The Indian pharmaceutical sector is estimated to reach $100 billion by 2025, accounting for 10% of the global pharmaceutical industry by volume. It currently accounts for 20% of global generic exports. The sector is expected to grow at a CAGR of 12.89% until 2020 to reach $55 billion. By 2020, India will be among the top 3 pharmaceutical markets by growth and 6th largest globally. The government has implemented policies and initiatives like 'PharmaVision 2020' to make India a global pharmaceutical leader and improve affordability and availability of medicines.
The document provides an overview of the pharmaceutical industry in India. Some key points:
- India is a major global player in pharmaceuticals, accounting for around 3% of the global industry. The market is expected to grow to $55 billion by 2020 and $100 billion by 2025.
- India has a large generics market and is a major exporter, accounting for 20% of global exports. Exports were $16.84 billion in 2016-17 and are projected to reach $20 billion by 2020.
- Key segments of the market include generics, Active Pharmaceutical Ingredients, Contract Research and Manufacturing Services, and biosimilars. Anti-infectives represent the largest segment dome
Indian pharmaceutical industry supplies over 50% of global demand for various vaccines and drugs. It is expected to grow at 22.4% annually to reach $55 billion by 2025. India accounts for 20% of global exports in generics. The domestic market is expected to reach $27.9 billion by 2020 with high potential for growth in generics. Increased investment in R&D and acquisitions are driving growth in the robust Indian pharmaceutical sector.
Indian pharmaceutical sector is estimated to account for 3.1-3.6% of the global pharmaceutical industry in value terms and 10% in volume terms. The country's pharmaceutical industry is expected to expand at a CAGR of 12.89% over 2015-2020 to reach US$ 55 billion. India accounts for 20% of global exports in generics. By 2020, India is likely to be among the top three pharmaceutical markets by incremental growth and 6th largest market globally in absolute size. The generics market stood at US$ 26.1 billion in 2016 and has high potential for growth. By 2024-25, India's biotech industry is estimated to increase to US$ 100 billion from US$ 11 billion in F
Indian pharmaceutical industry is the third largest in terms of volume and is expected to grow to US$ 55 billion by 2020. It supplies over 50% of global demand for various vaccines and HIV/AIDS medicines. India accounts for 20% of global exports in generics. Exports stood at US$ 17.27 billion in FY18 and are expected to reach US$ 20 billion by 2020. The domestic market is expected to reach US$ 27.9 billion by 2020. India has a competitive advantage due to its low cost of production which is approximately 33% lower than the US. The government aims to make India a global leader in drug manufacturing through initiatives like 'Pharma Vision 2020'.
Indian Pharmaceutical Market Overview 2013 by Nitesh BheleNitesh Bhele
The document summarizes the Indian pharmaceutical market in 2013. It highlights that the Indian market was valued at around $10 billion and was expected to grow double digits in the next five years. The generic drugs market was estimated to make up around 90% of the prescription drug market by 2016. It also provides an overview of the key segments of the Indian pharmaceutical market, the largest global companies, top therapeutic classes and products, as well as government initiatives to support industry growth.
Indian pharmaceutical industry supplies over 50% of global demand for various vaccines and generic drugs. The pharmaceutical sector was valued at US$33 billion in 2017 and is expected to grow at 15% annually. India accounts for 20% of global exports in generics. Major export destinations include North America, Africa, and the European Union. Indian companies are increasing R&D spending to develop new drugs and looking for growth opportunities in global markets through exports and acquisitions.
The document provides an overview of the pharmaceutical industry in India. Some key points:
- The Indian pharmaceutical industry is expected to grow at a CAGR of 12.89% until 2020 to reach $55 billion in size.
- India accounts for 20% of global exports in generics drugs. Exports stood at $16.84 billion in 2016-17 and are expected to reach $20 billion by 2020.
- The domestic pharmaceutical market was worth $27.57 billion in 2016 and is estimated to have grown 7.4% to $29.61 billion in 2017. The market is expected to continue growing rapidly over the next few years.
Indian pharmaceutical industry is the third largest in terms of volume and provides over 50% of global demand for various vaccines, 40% of generic demand in US, and 25% of all medicine in UK. It is expected to grow at 22.4% annually to $55 billion by 2025. India accounts for 20% of global exports in generics with exports reaching $17.27 billion in 2017-18. The domestic market is expected to reach $27.9 billion by 2020 driven by increased healthcare spending and penetration of health insurance in India. The industry has immense potential for growth in generics, biotech and contract manufacturing segments.
Indian pharmaceutical industry supplies over 50% of global demand for various vaccines and 40% of generic demand in the US. The pharmaceutical sector was valued at US$ 33 billion in 2017 and is expected to grow at 15% annually. India accounts for 20% of global exports in generics. Exports stood at US$ 17.27 billion in FY18 and are projected to reach US$ 20 billion by 2020. The domestic market is expected to reach US$ 27.9 billion by 2020. Increased investment in R&D, acquisitions, and partnerships are driving growth in the Indian pharmaceutical sector.
The pharmaceutical industry in India supplies over 50% of global demand for various vaccines and generic drugs. It is expected to grow at 22.4% annually to reach $55 billion by 2025. India accounts for 20% of global exports in generics. Exports stood at $17.27 billion in 2017-18 and are projected to reach $20 billion by 2020. The domestic market is expected to reach $27.9 billion by 2020, driven by growing healthcare needs and rising income levels. Indian companies are expanding globally through exports and overseas investments to boost sales and access new markets.
The document provides an overview of the pharmaceutical industry in India. Some key points:
1. The Indian pharmaceutical industry is expected to grow to $100 billion by 2025 from $27.57 billion in 2016, expanding at a CAGR of 12.89% between 2015-2020.
2. India accounts for 20% of global exports in generics drugs, with exports standing at $16.84 billion in 2016-17 and projected to reach $20 billion by 2020.
3. The domestic generics drugs market was valued at $26.1 billion in 2016 and has significant potential for further growth.
This is a very good presentation on Indian Pharmaceutical sector prepared by India Brand Equity Fund ( IBEF ) working under Commerce Ministry, Govt of India. A very good effort is made to cover all aspects of Indian pharma.They could have included ABLE also.
Industry CEOs can consider to use this ppt in overseas presentations.
The document provides an overview of the pharmaceutical industry in India. Some key points:
- India supplies over 50% of global demand for various vaccines and generic drugs. The pharmaceutical sector was valued at $33 billion in 2017 and is expected to reach $55 billion by 2022, growing at 22.4% CAGR.
- India accounts for 20% of global exports in generics. Pharmaceutical exports stood at $17.27 billion in 2017-18 and are expected to reach $20 billion by 2020.
- The domestic generics market is expected to reach $27.9 billion by 2020 and has immense growth potential. By 2024-25, the biotech industry is estimated to increase to $100 billion
India's oil and gas sector is dominated by state-owned companies. India is the third largest energy consumer globally and its energy demand is expected to double by 2035. Oil consumption has expanded at a CAGR of 4.78% during 2007-2017 to reach 4.69 million barrels per day in 2017, with India retaining its spot as the third largest oil consumer. Gas consumption has increased at a CAGR of 3.40% between 2007-2017 and demand is projected to further rise significantly by 2040. The country increasingly relies on imports to meet its growing demand for oil and gas.
Indian pharmaceutical sector accounts for about 2.4% of the global pharmaceutical industry in value terms and 10% in volume terms. The country's pharmaceutical industry is expected to expand at a CAGR of 12.89% over 2015–20 to reach US$ 55 billion, making it among the fastest growing industries. India exports 20% of global exports in generics, with pharmaceutical exports at US$ 16.8 billion in 2016-17 and projected to reach US$ 20 billion by 2020. The generics market stood at US$ 26.1 billion in 2016 with high potential for growth. By 2024-25, India's biotech industry is estimated to increase to US$ 100 billion from US$ 11 billion in FY 2015
This document provides an overview of the history and growth of the Indian pharmaceutical industry. It discusses how India's growing middle class and economy have increased healthcare spending and demand for drugs. It also summarizes how disease profiles are shifting towards more chronic conditions like diabetes. Government policies aim to improve healthcare access and spending. The pharmaceutical market and exports have grown significantly in recent decades and India has become a major supplier of generic drugs globally.
The document discusses the Indian pharmaceutical industry. It notes that India accounts for about 1.4% of the global pharma industry by value but 10% by volume. The industry is growing rapidly and is expected to reach $36 billion by 2016, expanding at a CAGR of 17.8%. India has a large and growing generics market, low-cost production, and government policy support promoting the pharmaceutical sector. The industry has significant export potential and is a major supplier of generic drugs globally.
The document provides an overview of the pharmaceutical industry in India. Some key points:
- The Indian pharmaceutical sector accounts for about 2.4% of the global pharmaceutical industry in value and is expected to grow at a CAGR of 12.89% to reach $55 billion by 2020.
- India accounts for 20% of global exports in generics drugs. Exports were $16.4 billion in 2016-17 and are expected to grow 30% to $20 billion by 2020.
- Generic drugs form the largest segment of the Indian pharmaceutical market, accounting for 70% of the market. Anti-infectives represent the largest therapeutic segment.
The document discusses India's advantages in low-
The document discusses projections for growth in the Indian pharmaceutical market from 2005 to 2015. Some key points:
1) The market is expected to triple in size, growing from $6.3 billion in 2005 to about $20 billion by 2015, making it one of the top 10 largest markets globally.
2) The incremental growth of $14 billion would make India the 3rd largest growth market after the US and China over this period.
3) Key drivers of growth are expected to be rising incomes, expansion of healthcare infrastructure, greater health insurance coverage, and increasing prevalence of chronic diseases.
The document provides an overview of the pharmaceutical industry in India. Some key points:
- India supplies over 50% of global demand for various vaccines and generic drugs. The pharmaceutical sector was valued at $33 billion in 2017 and is expected to reach $55 billion by 2022, growing at 22.4% CAGR.
- India accounts for 20% of global exports in generics. Pharmaceutical exports were $17.27 billion in 2017-18 and are projected to reach $20 billion by 2020.
- The domestic generics market is expected to reach $27.9 billion by 2020 and has immense growth potential. Generic drugs account for 70% of the domestic market.
1) By 2020, the Indian pharmaceutical industry is projected to grow to $50 billion and become one of the top 10 pharmaceutical markets globally, driven by strong domestic demand and increased exports.
2) Generics are expected to continue dominating the market, accounting for around 90% of the pharmaceutical formulation market. Patent-protected drugs will make up about 10% of the market.
3) Increased healthcare infrastructure investment, rising incomes, health insurance expansion, and government programs are expected to drive growth in domestic pharmaceutical demand and help increase accessibility of drugs across India. Chronic diseases will account for over half of the pharmaceutical market.
This document discusses growth opportunities for the Indian pharmaceutical industry through 2025. It identifies 6 value creation factors that can accelerate growth: 1) new products and business models through innovation, 2) new therapies for existing treatments, 3) affordability, 4) access to healthcare, 5) pricing strategies, and 6) marketing efficiencies. The current Indian pharmaceutical market is estimated at $7.5 billion based on retail sales, hospital sales, and generic sales. The industry can target growth by expanding in rural and urban markets, increasing treatment rates for conditions like diabetes, and introducing new products and therapies.
The document provides an overview of the pharmaceutical industry in India. Some key points:
- The Indian pharmaceutical industry is expected to grow at a CAGR of 12.89% until 2020 to reach $55 billion in size.
- India accounts for 20% of global exports in generics drugs and exports were $16.8 billion in 2016-17, expected to reach $20 billion by 2020.
- The generics market in India stands at $26.1 billion in 2016 and has strong growth potential.
- Major segments of the pharmaceutical industry in India include active pharmaceutical ingredients, formulations, biosimilars, and contract research and manufacturing.
This document contains photo credits from 10 different photographers for images that were likely used in a Haiku Deck presentation on SlideShare about being inspired. The photos come from a variety of sources including Philo Nordlund, Ju Muncinelli, Gulfu, woodleywonderworks, USDAgov, Ruud Onos, scottlum, found_drama, Gueorgui Tcherednitchenko, and Japanexperterna.se.
The hospital segment in India is becoming increasingly attractive for pharmaceutical companies due to its large size, fast growth rate, and investment opportunities. However, pharmaceutical companies will need to rethink their business strategies to succeed in this evolving market. Hospitals are exerting more control over physician prescriptions and purchasing decisions. Additionally, the relationship between physicians and hospitals is shifting, with hospitals gaining more influence. To effectively engage with the hospital segment, pharmaceutical companies will need to tailor their strategies, products, targeting, and metrics to the unique dynamics of each hospital type.
Indian pharmaceutical industry is the third largest in terms of volume and is expected to grow to US$ 55 billion by 2020. It supplies over 50% of global demand for various vaccines and HIV/AIDS medicines. India accounts for 20% of global exports in generics. Exports stood at US$ 17.27 billion in FY18 and are expected to reach US$ 20 billion by 2020. The domestic market is expected to reach US$ 27.9 billion by 2020. India has a competitive advantage due to its low cost of production which is approximately 33% lower than the US. The government aims to make India a global leader in drug manufacturing through initiatives like 'Pharma Vision 2020'.
Indian Pharmaceutical Market Overview 2013 by Nitesh BheleNitesh Bhele
The document summarizes the Indian pharmaceutical market in 2013. It highlights that the Indian market was valued at around $10 billion and was expected to grow double digits in the next five years. The generic drugs market was estimated to make up around 90% of the prescription drug market by 2016. It also provides an overview of the key segments of the Indian pharmaceutical market, the largest global companies, top therapeutic classes and products, as well as government initiatives to support industry growth.
Indian pharmaceutical industry supplies over 50% of global demand for various vaccines and generic drugs. The pharmaceutical sector was valued at US$33 billion in 2017 and is expected to grow at 15% annually. India accounts for 20% of global exports in generics. Major export destinations include North America, Africa, and the European Union. Indian companies are increasing R&D spending to develop new drugs and looking for growth opportunities in global markets through exports and acquisitions.
The document provides an overview of the pharmaceutical industry in India. Some key points:
- The Indian pharmaceutical industry is expected to grow at a CAGR of 12.89% until 2020 to reach $55 billion in size.
- India accounts for 20% of global exports in generics drugs. Exports stood at $16.84 billion in 2016-17 and are expected to reach $20 billion by 2020.
- The domestic pharmaceutical market was worth $27.57 billion in 2016 and is estimated to have grown 7.4% to $29.61 billion in 2017. The market is expected to continue growing rapidly over the next few years.
Indian pharmaceutical industry is the third largest in terms of volume and provides over 50% of global demand for various vaccines, 40% of generic demand in US, and 25% of all medicine in UK. It is expected to grow at 22.4% annually to $55 billion by 2025. India accounts for 20% of global exports in generics with exports reaching $17.27 billion in 2017-18. The domestic market is expected to reach $27.9 billion by 2020 driven by increased healthcare spending and penetration of health insurance in India. The industry has immense potential for growth in generics, biotech and contract manufacturing segments.
Indian pharmaceutical industry supplies over 50% of global demand for various vaccines and 40% of generic demand in the US. The pharmaceutical sector was valued at US$ 33 billion in 2017 and is expected to grow at 15% annually. India accounts for 20% of global exports in generics. Exports stood at US$ 17.27 billion in FY18 and are projected to reach US$ 20 billion by 2020. The domestic market is expected to reach US$ 27.9 billion by 2020. Increased investment in R&D, acquisitions, and partnerships are driving growth in the Indian pharmaceutical sector.
The pharmaceutical industry in India supplies over 50% of global demand for various vaccines and generic drugs. It is expected to grow at 22.4% annually to reach $55 billion by 2025. India accounts for 20% of global exports in generics. Exports stood at $17.27 billion in 2017-18 and are projected to reach $20 billion by 2020. The domestic market is expected to reach $27.9 billion by 2020, driven by growing healthcare needs and rising income levels. Indian companies are expanding globally through exports and overseas investments to boost sales and access new markets.
The document provides an overview of the pharmaceutical industry in India. Some key points:
1. The Indian pharmaceutical industry is expected to grow to $100 billion by 2025 from $27.57 billion in 2016, expanding at a CAGR of 12.89% between 2015-2020.
2. India accounts for 20% of global exports in generics drugs, with exports standing at $16.84 billion in 2016-17 and projected to reach $20 billion by 2020.
3. The domestic generics drugs market was valued at $26.1 billion in 2016 and has significant potential for further growth.
This is a very good presentation on Indian Pharmaceutical sector prepared by India Brand Equity Fund ( IBEF ) working under Commerce Ministry, Govt of India. A very good effort is made to cover all aspects of Indian pharma.They could have included ABLE also.
Industry CEOs can consider to use this ppt in overseas presentations.
The document provides an overview of the pharmaceutical industry in India. Some key points:
- India supplies over 50% of global demand for various vaccines and generic drugs. The pharmaceutical sector was valued at $33 billion in 2017 and is expected to reach $55 billion by 2022, growing at 22.4% CAGR.
- India accounts for 20% of global exports in generics. Pharmaceutical exports stood at $17.27 billion in 2017-18 and are expected to reach $20 billion by 2020.
- The domestic generics market is expected to reach $27.9 billion by 2020 and has immense growth potential. By 2024-25, the biotech industry is estimated to increase to $100 billion
India's oil and gas sector is dominated by state-owned companies. India is the third largest energy consumer globally and its energy demand is expected to double by 2035. Oil consumption has expanded at a CAGR of 4.78% during 2007-2017 to reach 4.69 million barrels per day in 2017, with India retaining its spot as the third largest oil consumer. Gas consumption has increased at a CAGR of 3.40% between 2007-2017 and demand is projected to further rise significantly by 2040. The country increasingly relies on imports to meet its growing demand for oil and gas.
Indian pharmaceutical sector accounts for about 2.4% of the global pharmaceutical industry in value terms and 10% in volume terms. The country's pharmaceutical industry is expected to expand at a CAGR of 12.89% over 2015–20 to reach US$ 55 billion, making it among the fastest growing industries. India exports 20% of global exports in generics, with pharmaceutical exports at US$ 16.8 billion in 2016-17 and projected to reach US$ 20 billion by 2020. The generics market stood at US$ 26.1 billion in 2016 with high potential for growth. By 2024-25, India's biotech industry is estimated to increase to US$ 100 billion from US$ 11 billion in FY 2015
This document provides an overview of the history and growth of the Indian pharmaceutical industry. It discusses how India's growing middle class and economy have increased healthcare spending and demand for drugs. It also summarizes how disease profiles are shifting towards more chronic conditions like diabetes. Government policies aim to improve healthcare access and spending. The pharmaceutical market and exports have grown significantly in recent decades and India has become a major supplier of generic drugs globally.
The document discusses the Indian pharmaceutical industry. It notes that India accounts for about 1.4% of the global pharma industry by value but 10% by volume. The industry is growing rapidly and is expected to reach $36 billion by 2016, expanding at a CAGR of 17.8%. India has a large and growing generics market, low-cost production, and government policy support promoting the pharmaceutical sector. The industry has significant export potential and is a major supplier of generic drugs globally.
The document provides an overview of the pharmaceutical industry in India. Some key points:
- The Indian pharmaceutical sector accounts for about 2.4% of the global pharmaceutical industry in value and is expected to grow at a CAGR of 12.89% to reach $55 billion by 2020.
- India accounts for 20% of global exports in generics drugs. Exports were $16.4 billion in 2016-17 and are expected to grow 30% to $20 billion by 2020.
- Generic drugs form the largest segment of the Indian pharmaceutical market, accounting for 70% of the market. Anti-infectives represent the largest therapeutic segment.
The document discusses India's advantages in low-
The document discusses projections for growth in the Indian pharmaceutical market from 2005 to 2015. Some key points:
1) The market is expected to triple in size, growing from $6.3 billion in 2005 to about $20 billion by 2015, making it one of the top 10 largest markets globally.
2) The incremental growth of $14 billion would make India the 3rd largest growth market after the US and China over this period.
3) Key drivers of growth are expected to be rising incomes, expansion of healthcare infrastructure, greater health insurance coverage, and increasing prevalence of chronic diseases.
The document provides an overview of the pharmaceutical industry in India. Some key points:
- India supplies over 50% of global demand for various vaccines and generic drugs. The pharmaceutical sector was valued at $33 billion in 2017 and is expected to reach $55 billion by 2022, growing at 22.4% CAGR.
- India accounts for 20% of global exports in generics. Pharmaceutical exports were $17.27 billion in 2017-18 and are projected to reach $20 billion by 2020.
- The domestic generics market is expected to reach $27.9 billion by 2020 and has immense growth potential. Generic drugs account for 70% of the domestic market.
1) By 2020, the Indian pharmaceutical industry is projected to grow to $50 billion and become one of the top 10 pharmaceutical markets globally, driven by strong domestic demand and increased exports.
2) Generics are expected to continue dominating the market, accounting for around 90% of the pharmaceutical formulation market. Patent-protected drugs will make up about 10% of the market.
3) Increased healthcare infrastructure investment, rising incomes, health insurance expansion, and government programs are expected to drive growth in domestic pharmaceutical demand and help increase accessibility of drugs across India. Chronic diseases will account for over half of the pharmaceutical market.
This document discusses growth opportunities for the Indian pharmaceutical industry through 2025. It identifies 6 value creation factors that can accelerate growth: 1) new products and business models through innovation, 2) new therapies for existing treatments, 3) affordability, 4) access to healthcare, 5) pricing strategies, and 6) marketing efficiencies. The current Indian pharmaceutical market is estimated at $7.5 billion based on retail sales, hospital sales, and generic sales. The industry can target growth by expanding in rural and urban markets, increasing treatment rates for conditions like diabetes, and introducing new products and therapies.
The document provides an overview of the pharmaceutical industry in India. Some key points:
- The Indian pharmaceutical industry is expected to grow at a CAGR of 12.89% until 2020 to reach $55 billion in size.
- India accounts for 20% of global exports in generics drugs and exports were $16.8 billion in 2016-17, expected to reach $20 billion by 2020.
- The generics market in India stands at $26.1 billion in 2016 and has strong growth potential.
- Major segments of the pharmaceutical industry in India include active pharmaceutical ingredients, formulations, biosimilars, and contract research and manufacturing.
This document contains photo credits from 10 different photographers for images that were likely used in a Haiku Deck presentation on SlideShare about being inspired. The photos come from a variety of sources including Philo Nordlund, Ju Muncinelli, Gulfu, woodleywonderworks, USDAgov, Ruud Onos, scottlum, found_drama, Gueorgui Tcherednitchenko, and Japanexperterna.se.
The hospital segment in India is becoming increasingly attractive for pharmaceutical companies due to its large size, fast growth rate, and investment opportunities. However, pharmaceutical companies will need to rethink their business strategies to succeed in this evolving market. Hospitals are exerting more control over physician prescriptions and purchasing decisions. Additionally, the relationship between physicians and hospitals is shifting, with hospitals gaining more influence. To effectively engage with the hospital segment, pharmaceutical companies will need to tailor their strategies, products, targeting, and metrics to the unique dynamics of each hospital type.
The document discusses the history and context around why the United States does not have universal healthcare. It traces the evolution of the healthcare system from the early 1900s through various reforms. While many argue universal healthcare could help prevent deaths and bankruptcy, others believe it would burden taxpayers as it is not free. Historically, the US healthcare system has undergone shifts between private and public involvement through reforms. Legislatively, the checks and balances system and power of private sectors have made it difficult for universal healthcare legislation to pass due to concerns over costs and government control of the economy.
The document discusses how to compress images in PowerPoint presentation slides to reduce their file size. It provides two methods for compressing images - right clicking an image and saving it as a JPG before reinserting into the presentation, or selecting the image and compressing it to a lower resolution directly in PowerPoint by changing the format. Compressing images can make the first slide, which tends to be heaviest, and the overall presentation size smaller for sharing through email or other means.
By Mr. Irish Pereira The current and expected usage of redox flow batteries across the World.
Includes usage of redox batteries in power generation sectors, including market trends.
OTC Drug marketing is a different ball game all together than the ethical sales promotional model, being used by the pharmaceuticals companies. As the core idea of OTC Drugs marketing is pushing of sales, the sales promotion model has to be different. This presentation outlines a sales promotional model for the OTC Drug marketers in India.
The 2016 IMS APAC Insight Magazine provide insights to unveils new areas of play, new methodologies and new geographies that are poised to disrupt the healthcare landscape in this region.
India is one of the emerging markets which is offering significant growth potential for the industry. This presentation provides a glance of Indian Pharmaceutical Market with more insights into Indian OTC drug markets, its current scenario as well as strategies for ensuring higher sales returns.
Wonders of Portfolio = Long Term Planning + AgilityAtlassian
At comScore, we’ve planned a year’s worth of work for an organization of 140+ members across multiple teams, with several business units all collaborating on various projects. And like many, we’re an organization trying to stay agile along the way. Learn about our successes and lessons that got us to this point, and how implementing Portfolio for JIRA has changed the way we plan.
We’ll go into how we do Capacity Planning, People Management, Schedule Management, and Reporting, with insight from both a PM and Engineering Manager. Find out how teams can leverage Portfolio to strategically plan and quickly adapt to a changing landscape, and track progress on their projects.
Products covered:
Portfolio for JIRA
The document provides an overview of the Indian healthcare industry and infrastructure. It notes that the industry is growing rapidly at 17% CAGR and is projected to reach $280 billion by 2020. Key drivers of growth include rising incomes, health awareness, lifestyle diseases, and insurance penetration. However, healthcare spending and infrastructure in India remains low compared to global standards. The private sector dominates healthcare delivery, accounting for around 80% of total spending. The government is taking initiatives to boost diagnostic infrastructure through public-private partnerships.
Indian Pharmaceutical Export Market - Top Export Destinations for Indian Phar...Irish Pereira
By Mr. Irish Pereira. The report present snapshot of Indian Pharmaceutical industry in both domestic as well as export market. It is collation of facts pertaining to Indian pharma exports and explore key emerging trends pertaining to pharma export market. It describes key players of Indian pharma market and their export orientation as in their target export destinations, their focus therapies etc.
Fact sheet:
1) Indian Pharma Market size 2015
2) Indian pharmaceutical market segments by value
3)Patented (Innovator) Vs Generics Scenario
4)Growth drivers of Indian pharmaceutical industry
5) Indian Pharmaceutical sector – SWOT Analysis
6)PHARMEXCIL – Facilitating agency for Indian Pharma Exports
7) Indian Pharmaceutical Exports (USD bn)
8)Formulations share in Total Pharma Exports (2014-15)
9) Top 25 destination countries of India’s pharmaceutical exports during 2013-14 (INR mn)
10) Major Indian Pharma Companies (By Revenue-USD mn)
11) Pharma players and their export destinations
Sun Pharma,Dr. Reddy’s Lab,
CIPLA, Lupin, Aurobindo, Cadila Healthcare, Torrent Pharma, Wockhardt,
12) Emerging trends in Indian Pharma Market
This document discusses how established companies can create new growth opportunities in innovative ways. It outlines an innovative framework consisting of five principles for business design thinking: understanding customer needs, collaboration and co-creation, human-centered focus, visual thinking and storytelling, and taking a holistic perspective. The document provides examples and discusses components like offerings, business models, revenue models, and crafting a strategy. It promotes discovering opportunities by focusing on underserved customer needs and outlines various activities, templates, and a workshop for applying business design thinking.
Demonetization - Impact on Indian PharmaAnup Soans
- Total sales for the pharmaceutical company remain lower than the same period in October due to the demonetization of high value currency notes in India. Acute therapy sales have been most severely impacted and are down 20% in November compared to October. Chronic therapy sales have benefited and are up 10-15% as some patients preponed medicine purchases for 2-3 months using old notes. Sub-chronic therapy sales have been the most stable with only a marginal dip or rise between weeks. Inventory levels remain high across therapies due to extended credit periods offered by companies.
Why are there only 15% to 20% Women in Indian Pharma?Anup Soans
Guest Editorial - Gender Gap in Indian Pharma - An Unaddressed Issue
..............................................................................
Inside this Issue
1. A Salesforce Retention Strategy for Indian Pharma by K. Hariram
A quantitative and qualitative approach to measuring and stemming the tide of attrition in pharma sales.
2. “I Am Waiting for the Day When Pharma Hires a CEO from a Tech Company” an Interview with Salil Kallianpur
Salil Kallianpur – Executive Vice President – Primary Care at GSK shares his thoughts on Indian pharma in 2017 and beyond with MedicinMan.
3. 1st World Pharma Brand Managers Day by Prof. Suniel Deshpande and Vivek Hattangadi
A report on the 1st World Pharma Brand Managers Day which began with a Pharma CEO Conclave.
4. Pharma L&D Beyond the Classroom by Diksha Fouzdar
Real learning almost always takes place outside the classroom, but internalizing that in L&D requires a mindset change.
Retail Sales of Drugs - Impact of Demonetization Anup Soans
The Government of India’s well-intentioned move to de-monetize currency notes of INR 500 and INR 1000, has been expected to cause near-term business disruptions across sectors. Within pharmaceuticals, this has implications for different stakeholders, ranging from pharmaceutical companies to distribution channel,
patients & physicians.
In an attempt to understand the effect of the announcement on the drug distribution network, QuintilesIMS conducted a survey across roughly 500+ chemists around the country. The objective was to understand short-term as well as potentially lingering effects of the demonetization move. Key points of investigation
ranged from the immediate impact on individual chemist sales & patient footfall to value chain-related aspects such as credit cycles, supply levels, inventory stock levels, etc. as well as measures taken by retailers to manage the effect of the demonetization announcement.
This document captures the essence of the study results
The document discusses production planning in SAP. It covers key modules like sales and operations planning, master production scheduling, material requirements planning, bills of material, work centers, routings and operation costing. The goal of production planning is to integrate sales forecasts with manufacturing capabilities to generate production and procurement plans.
While healthcare consumption will likely continue to grow, industry profit pools may not expand over the next three years due to COVID-19. Healthcare players who develop innovative business models will create disproportionate value. New models are beginning to show promise in delivering better care and higher returns through greater alignment of incentives, better integration of care, and use of data analytics. Payers using next-generation managed care models and providers integrating a range of care delivery assets have demonstrated superior financial returns.
A new report from PwC’s Health Research Institute predicts that insurance companies will be spending more to pay for prescription drugs starting next year, from around 3% to almost 6% by 2027. Here’s more forecasts on medical spending from the report:
•Generics: Almost half of the estimated sales from the top 100 brand-name drugs won’t be affected by generic competition for another three years.
•Specialty drugs: Spending on specialty drugs — such as biologics or rare disease treatments — has already been growing over the past five years, but by 2020 these drugs may make up more than half of all U.S. drug spending.
•Chronic disease: 85% of all employer-provided insurance spending is on chronic conditions, and obesity and diabetes will be the two top conditions that will account for spending in 2020.
Mercer Capital's Value Focus: Medical Technology | Q2 2022Mercer Capital
The document provides a summary of a quarterly report from Mercer Capital on the medtech and device industry for Q2 2022. It includes a review of market performance, valuation multiples, operating metrics, M&A activity, and IPOs during Q1 2022. It also discusses Mercer Capital's experience providing valuation services to companies in the sector. The summary focuses on key trends in the industry including demographic shifts driving demand, healthcare spending growth in the US, the impact of third-party reimbursement, competitive factors, and regulatory environment.
DELOITTE: 2017 Global Health Sciences Outlook Report - A global perspective on the healthcare industry and its strategic sectors. Deloitte efficiently delivers an uncomplicated but in-depth look at worldwide healthcare. Rising demand and associated spending are being fueled by an aging population; the growing prevalence of chronic diseases and comorbidities; development of costly clinical innovations; increasing patient awareness, knowledge, and expectations; and continued economic uncertainty despite regional pockets of recovery are just a few of the key issues and trends impacting the global health care sector.
Connect with me at LinkedIn and Twitter, visit my healthcare website -an industry resource since 2004...
Twitter: @johngbaresky
LinkedIn: https://www.linkedin.com/in/johngbaresky
My website: www.healthcaremedicalpharmaceuticaldirectory.com
John Baresky Healthcare Marketing Leader, Pharmaceutical Marketing, Digital Marketing Strategy, Content Marketing Strategy, Market Access Strategy, Healthcare RPA Software Marketing Strategy
The 10 companies booming in healthcare sector smallinsightscare
Development is a continuous process in any sector. It brings in more comfort, more precision, and more enhanced way of living.Acknowledging the remarkable contribution of the leading companies in the care sector, we bring to you the special issue of “The 10 Companies Booming in Healthcare Sector”.
Bloomberg Intelligence: US Healthcare Outlook 2015Bloomberg LP
Entering 2015, impacts of the Affordable Care Act will continue to shape the healthcare landscape for both patients and providers. The industry may also see new product launches from medical device companies looking to offset stagnant sales.
The Indian pharmaceutical industry is the third largest in volume and thirteenth largest in value globally. Total healthcare spending in India is expected to grow 20% annually to $280 billion by 2020 from $65 billion currently. The pharmaceutical industry specifically is expected to grow 12.1% annually to $45 billion by 2020. Growth drivers for the industry include rising incomes, health insurance penetration, and cost advantages of manufacturing generics in India. However, the industry faces challenges such as stringent price controls, lack of data protection, competition from other emerging markets, and attracting and retaining talent. The Indian government is taking initiatives to support the industry through R&D funding, tax benefits, and improving infrastructure and logistics networks.
GetWell operates over 2,000 drug stores across 5 European countries. The project aims to build a predictive model to forecast 4 weeks of daily sales for 1,000 GetWell stores in Germany. This will help optimize staffing schedules and inventory levels. The model seeks to understand various influencing factors like promotions, holidays, and competition to generate consistent sales forecasts.
The 10 Companies Booming in Healthcare Sectorinsightscare
Acknowledging the remarkable contribution of the leading companies in the care sector, we bring to you the special issue of “The 10 Companies Booming in Healthcare Sector”. This edition portrays the inspiring stories of the listed pre-eminent organizations that are shaping the future of healthcare through innovation and dedication.
Chris Evert, the Chief Supply Chain Officer of Medical Technologies Corporation, must find major cost savings to offset taxes imposed by the Affordable Care Act. The U.S. medical device industry faces pricing pressures from group purchasing organizations that consolidate hospital purchases. Medical device manufacturers rely on distributors to supply products to hospitals, but distributors have narrow margins and cannot fully pass on tax increases. Large hospital systems are forming through consolidation to manage costs in a shifting reimbursement environment focused on patient outcomes rather than service volume.
This newsletter provides updates on healthcare reform and its costs, workplace wellness programs, and medical clinics. It discusses how the Affordable Care Act will pay for expanding coverage, including new taxes starting in 2011-2018 on drug companies, insurers, and high-cost plans. It also links obesity to higher workers compensation costs and recommends integrating workplace safety with wellness efforts. Finally, it notes the growth of retail medical clinics and their lower costs compared to doctors' offices and emergency rooms.
5 Trends to Watch in the Medical Device Industry in 2016Mercer Capital
Demographic shifts underlie the long-term market opportunity for medical device manufacturers. While efforts to control costs on the part of the government insurer in the U.S. may limit future pricing growth for incumbent products, a growing global market provides domestic device manufacturers with an opportunity to broaden and diversify their geographic revenue base. Developing new products and procedures is risky and usually more resource intensive compared to some other growth sectors of the economy. However, barriers to entry in the form of existing regulations provide a measure of relief from competition, especially for newly developed products.
The document summarizes the investment outlook for the Indian healthcare and lifesciences sector in 2023 according to Kapil Khandelwal of Toro Finserve and EquNev Capital. It predicts a moderate outlook overall as healthcare spending falls due to high inflation and slow economic growth. Digitalization will continue but health data regulation will tighten. Some segments like healthcare insurance are predicted to be "hot" while others like providers and health retail will see margin pressures. The document outlines factors that could positively or negatively impact investment across various industry segments in 2023.
Medical second opinion market Size, Share, Growth Business Strategy and Forec...jitendra more
Increasing number of errors in medical billing is also one of the prominent factors responsible for the growth of the market. For instance,according to a study published by the Medical Billing Advocates of America in2019, an estimated 80.0% of medical bills contain at least one error. Further,problems in medical billing errors cost a total of ~US$ 210 billion each year in the US. These possibilities and occurrences of financial errors areprojected to accelerate the growth of the medical second opinion market by 2027.
Health Information Exchange Market Size, Share | 2020-2025johnnyandrew4
The health information exchange market is projected to reach USD 2.0 billion by 2025 from USD 1.1 billion in 2020, at a CAGR of 12.2% during the forecast
Market research for Indian Pharmaceutical Market switching over from prescribed to OTC products. Scope of Indian Pharmaceutical OTC market, opportunities and challenges.
The document provides an overview of the Indian pharmaceutical market. It discusses key trends in the market including its size, growth drivers, segments and future scope. Some of the main points covered are:
- The Indian pharma market is the 3rd largest by volume and 10th by value, with domestic sales of $6 billion and exports of $6.3 billion. It is expected to grow at 14% annually to $47 billion by 2018.
- Branded generics dominate at 90% of the market. Chronic therapies are growing faster than acute therapies. Rural markets represent 20% of the market currently and are seen as the next growth frontier.
- Key growth drivers include population expansion, a growing middle class
The document discusses four key concepts for medical device executives to understand in order to succeed in China's rapidly growing medical devices market. First, executives must seize China's market opportunities as the market is expected to reach $50 billion by 2017. Second, they must understand the Chinese government's important role in regulating the industry and procurement processes. Third, executives should monitor healthcare reforms that could impact market access. Fourth, local competition is growing, so companies must balance global and local strategies to stay competitive. The medical devices market in China offers great potential for growth but also complexity that executives must navigate carefully.
The document summarizes a report projecting growth in the Indian pharmaceutical market from 2005 to 2015. Key points:
- The market is projected to triple in size from $6.3 billion in 2005 to $20 billion in 2015, driven mainly by rising incomes and expansion of medical infrastructure.
- India will become the 10th largest pharmaceutical market globally by 2015, with incremental growth of $14 billion being the 3rd largest of any market.
- While specialty therapies will increase their share from 35% to 45% of the market, mass therapies will remain important due to untreated conditions and more people rising above poverty.
- The largest drivers of growth will be rising incomes (40% of growth) and improved
New UCPMP Guidelines for Pharma companies Responsible for Compliance (Department of Pharmaceutical , Ministry of chemicals & Fertilizers, GOI )
feedback - niteshbhele@gmail.com
1) Merck's Januvia dominated the DPP-IV inhibitor class in developed markets due to being first to market and aggressive promotion, capturing 80% of sales.
2) However, in emerging markets Novartis' Galvus and fixed-dose combination Eucreas outperformed, capturing over 50% of the DPP-IV market in countries like Brazil, India, and Russia.
3) Late entrants to the DPP-IV class and future SGLT-2 class will need to focus on differentiation, emerging markets, and combination products to gain competitive advantage in the crowded diabetes drug market.
Business plan medical tourism in indiaNitesh Bhele
Medical tourism provides patients opportunities to receive quality healthcare in foreign countries like India at lower costs than in Western countries. The document outlines plans to start a medical tourism company in India called Med Tour Pvt. Ltd. that will arrange affordable cosmetic surgeries, non-elective procedures, and alternative medicine for international patients. It discusses the market size, services offered, strategies, finances, and human resources required to launch and run the business. The company aims to achieve profitability within its first year of operation through gradual growth in client numbers each month.
The document discusses the 2010 European debt crisis, its causes, and its impact on several European countries including Portugal, France, and Germany. It also outlines some of the policy reactions from European leaders and institutions to address the crisis, such as establishing the European Financial Stability Facility and European Financial Stabilization Mechanism to provide loans to countries in financial trouble.
Market research health drinks in india.Nitesh Bhele
This document summarizes a market research report on health drinks in India. It finds that Bournvita has the largest market share of 40% among the major brands. Complan has the second highest share at 22%. Most respondents are influenced by brand and taste when selecting drinks. While there is no significant gender or education impact, higher-income individuals consume more expensive brands. The market is growing at 4% annually but more awareness campaigns are needed. Expanding rural distribution could further increase consumption.
This document discusses biosensors and diagnostic products. It defines a biosensor as a device that combines a biological component with a physicochemical detector to detect analytes. It describes different types of biosensors including calorimetric, potentiometric, electrochemical and optical biosensors. It also discusses applications of biosensors in glucose monitoring, environmental monitoring, and pathogen detection. The document then defines diagnostic products and provides an overview of the diagnostic market in India including types, size, growth rate and examples.
Advertising is a form of paid, public communication used to inform and motivate consumers about products, services, ideas, and organizations. The goal is to change consumer behavior and persuade people to take a desired action, like purchasing a product. Advertisements provide information to help consumers make better choices, but critics argue they also manipulate tastes and impede competition by making products seem more differentiated than they are. Supporters counter that advertising enhances market efficiency by conveying price and product information and allowing new firms to more easily attract customers.
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotesPsychoTech Services
A proprietary approach developed by bringing together the best of learning theories from Psychology, design principles from the world of visualization, and pedagogical methods from over a decade of training experience, that enables you to: Learn better, faster!
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Oleg Kshivets
Overall life span (LS) was 1671.7±1721.6 days and cumulative 5YS reached 62.4%, 10 years – 50.4%, 20 years – 44.6%. 94 LCP lived more than 5 years without cancer (LS=2958.6±1723.6 days), 22 – more than 10 years (LS=5571±1841.8 days). 67 LCP died because of LC (LS=471.9±344 days). AT significantly improved 5YS (68% vs. 53.7%) (P=0.028 by log-rank test). Cox modeling displayed that 5YS of LCP significantly depended on: N0-N12, T3-4, blood cell circuit, cell ratio factors (ratio between cancer cells-CC and blood cells subpopulations), LC cell dynamics, recalcification time, heparin tolerance, prothrombin index, protein, AT, procedure type (P=0.000-0.031). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and N0-12 (rank=1), thrombocytes/CC (rank=2), segmented neutrophils/CC (3), eosinophils/CC (4), erythrocytes/CC (5), healthy cells/CC (6), lymphocytes/CC (7), stick neutrophils/CC (8), leucocytes/CC (9), monocytes/CC (10). Correct prediction of 5YS was 100% by neural networks computing (error=0.000; area under ROC curve=1.0).
These lecture slides, by Dr Sidra Arshad, offer a simplified look into the mechanisms involved in the regulation of respiration:
Learning objectives:
1. Describe the organisation of respiratory center
2. Describe the nervous control of inspiration and respiratory rhythm
3. Describe the functions of the dorsal and respiratory groups of neurons
4. Describe the influences of the Pneumotaxic and Apneustic centers
5. Explain the role of Hering-Breur inflation reflex in regulation of inspiration
6. Explain the role of central chemoreceptors in regulation of respiration
7. Explain the role of peripheral chemoreceptors in regulation of respiration
8. Explain the regulation of respiration during exercise
9. Integrate the respiratory regulatory mechanisms
10. Describe the Cheyne-Stokes breathing
Study Resources:
1. Chapter 42, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 36, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 13, Human Physiology by Lauralee Sherwood, 9th edition
Cell Therapy Expansion and Challenges in Autoimmune DiseaseHealth Advances
There is increasing confidence that cell therapies will soon play a role in the treatment of autoimmune disorders, but the extent of this impact remains to be seen. Early readouts on autologous CAR-Ts in lupus are encouraging, but manufacturing and cost limitations are likely to restrict access to highly refractory patients. Allogeneic CAR-Ts have the potential to broaden access to earlier lines of treatment due to their inherent cost benefits, however they will need to demonstrate comparable or improved efficacy to established modalities.
In addition to infrastructure and capacity constraints, CAR-Ts face a very different risk-benefit dynamic in autoimmune compared to oncology, highlighting the need for tolerable therapies with low adverse event risk. CAR-NK and Treg-based therapies are also being developed in certain autoimmune disorders and may demonstrate favorable safety profiles. Several novel non-cell therapies such as bispecific antibodies, nanobodies, and RNAi drugs, may also offer future alternative competitive solutions with variable value propositions.
Widespread adoption of cell therapies will not only require strong efficacy and safety data, but also adapted pricing and access strategies. At oncology-based price points, CAR-Ts are unlikely to achieve broad market access in autoimmune disorders, with eligible patient populations that are potentially orders of magnitude greater than the number of currently addressable cancer patients. Developers have made strides towards reducing cell therapy COGS while improving manufacturing efficiency, but payors will inevitably restrict access until more sustainable pricing is achieved.
Despite these headwinds, industry leaders and investors remain confident that cell therapies are poised to address significant unmet need in patients suffering from autoimmune disorders. However, the extent of this impact on the treatment landscape remains to be seen, as the industry rapidly approaches an inflection point.
Rasamanikya is a excellent preparation in the field of Rasashastra, it is used in various Kushtha Roga, Shwasa, Vicharchika, Bhagandara, Vatarakta, and Phiranga Roga. In this article Preparation& Comparative analytical profile for both Formulationon i.e Rasamanikya prepared by Kushmanda swarasa & Churnodhaka Shodita Haratala. The study aims to provide insights into the comparative efficacy and analytical aspects of these formulations for enhanced therapeutic outcomes.
Does Over-Masturbation Contribute to Chronic Prostatitis.pptxwalterHu5
In some case, your chronic prostatitis may be related to over-masturbation. Generally, natural medicine Diuretic and Anti-inflammatory Pill can help mee get a cure.
1. To win in a shifting profit pool, companies need to improve
how healthcare is delivered
By George Eliades, Michael Retterath, Norbert Hueltenschmidt
and Karan Singh
Healthcare 2020
3. Healthcare 2020
1
We have been talking about healthcare costs for more
than 40 years, but the worldwide financial crisis and
subsequent climate of austerity are finally catalyzing
change. Payers are searching for all available tools to
stunt the growth of a sector that has successfully resisted
cost containment for decades. Adding to the urgency
for action is an anticipated global surge in demand
precipitated by several factors: an aging population with
chronic care needs, population and income growth in
emerging markets and the potential for insurance
coverage expansion due to health reform in the US
and around the globe.
An increase in demand—even one accompanied by cost
pressures—is generally good for companies supplying
products to the healthcare sector. But in this case, it is
concomitant with a precipitous decline in research and
development productivity for pharmaceutical and medical
technology companies, leading to a more than $100 billion
loss in product exclusivity by 2015.1
Despite ongoing
medical need across many diseases, these players can
no longer depend on their innovation engine and pricing
power to drive ongoing profit growth. The net result will
be an unprecedented decline in the share of the overall
healthcare profit pool captured by innovation-driven
companies in favor of lower-margin sectors like generic
manufacturers and providers.2
We do not suggest that healthcare will be less innovative
over the coming decade, but rather that the focus of
innovation will shift from the product arena to healthcare
delivery. A demand surge in an environment of fiscal
constraint and slower product innovation will create a
climate that favors investment in new ways of deliver-
ing care, in part by applying the power of information
technology—long overdue in healthcare, relative to other
sectors. Indeed, the shift in emphasis from managing
inputs, like the rate of adoption of new products and the
number of physician visits, toward delivering outputs,
like patient satisfaction, clinical outcomes and overall
system savings, is already well underway.
Going forward, the critical question for companies will
be how they can evolve their business model and thrive
in a world of shifting profit pools by focusing on deliver-
ing better outputs, rather than by simply generating
more inputs—more products, more procedures and
ultimately more cost to the payers.
All of these disruptive changes will have two significant
implications for the global healthcare market:
• There will be radical changes in the relative size and
growth of the various parts of the global healthcare
profit pool. In the past, growth by sector has been
relatively consistent, but by 2020 and beyond, growth
rates across sectors and geographies will diverge.
• The basis of competition in the marketplace will
change as well. Different therapeutic areas will be
affected in distinct ways by two significant trends:
growing consumer engagement and increasing
standardization of care (“protocolization”).3
How will you compete as global profit
pools shift?
Even though the global profit pool will expand over the
next 10 years, most players will need to develop new
business models to win. We believe the total profit pool
will grow at a compound adjusted growth rate (CAGR)
of 4%—from $520 billion in 2010 to $740 billion in
2020—but lag overall healthcare expenditure as profit-
ability declines in aggregate worldwide
4
(see Figure 1).
Your business plans for the next decade will require a
deeper understanding of the sector and regional shifts
embedded in these global figures. For example, most
of the growth in the global profit pool will come from
increased volume in the delivery of care, while another
significant source of growth will come from smaller sec-
tors like contract research or manufacturing and nu-
trition, which are experiencing significant growth from
a smaller base, particularly in the emerging markets.
Pharmaceutical companies will see low growth and some
decline in margins over the coming decade. Brand-name
pharmaceuticals will grow only 1%, and the market will
become increasingly fragmented, as the main source of
revenue growth will be smaller items like targeted oncol-
ogy products.5
In the US the situation will be even worse,
as the forecasted 1% growth rate will depend on substan-
tial growth in the second half of the decade, overcoming
patent expirations and pricing pressures. At the same
time, generics will grow by 7%, driven by those same pat-
ent expirations as well as increased volume in emerging
markets (and a few underpenetrated developed markets).
4. 2
Healthcare 2020
Figure 1: By 2020, the global profit pool is expected to shift in several ways
Note: Insurance US reflects total health plan premiums; CXO represents contract research, manufacturing and sales organizations
Sources: IMS; Datamonitor; Business Insights; Freedonia; annual reports; analyst reports; CMS; OECD; Bain analysis
0
10
20
30%
23
15
18
1
4 4 4 5 5
6 6
EBIT margin
16
16
11
14
12
495 1,733 501 266 450 260 55 64230 100 260 44 62 850 890 2,280
Revenue
(2010, $B):
Total=$520B
0
10
20
30%
19
13
1616
Hospital
Retail pharmacy
Distribution
CXO
IVD
Medtech
Pharma OTC
Pharma Gx
1
Retail
pharmacy
3
Hospital
4
Other providers
4
Care
PBM
Insurance US
Insurance non US
HC IT
Nutrition
4 4
5 5
EBIT margin
Pharma
Rx
12
14
665 2,826 897 324 733 466 143 115497 148 385 79 144 1,258 1,317 3,714
Revenue
(2020, $B):
3% 5% 6% 2% 5% 5% 10% 6%7% 4% 4% 6% 9% 4% 4% 5%
CAGR
(10–20):
Total=$740B
Global healthcare profit pool (2010)
Global healthcare profit pool (2020)
Pharma
Rx
Distribution
CXO
IVD
Medtech
Pharma OTC
Pharma Gx
Other providers
Care
PBM
Insurance US
Insurance non US
HC IT
Nutrition
16
5. Healthcare 2020
3
Global medical technology products will grow 3%, but
with lower profit margins due primarily to worldwide
pricing pressure. The slowdown will come mainly from
peak penetration of products, such as stents, in devel-
oped markets and competition everywhere from “good
enough” products. In China there is already fierce com-
petition from locally produced stents, and this pricing
pressure will continue as the Chinese and others develop
cheaper alternatives.6
New healthcare value chain players will expand the
overall profit pool to some degree. While margins in
almost every other sector will slow, the growth in these
sectors will be dramatic. Contract research, manufac-
turing and sales companies and healthcare IT companies
will see significant volume growth as pharmaceutical
companies outsource more functions and the demand
for data accelerates.7
Contract research organizations
will expand through greater use of strategic alliances
and risk-sharing arrangements with pharmaceutical
companies. Contract manufacturing organizations will
see 8% CAGR, in part due to their expansion into China
and India.
Because of the uncertainty of health reform in the US,
payers are not likely to experience the growth they have
experienced in the past. Even if there is more insurance
coverage, there will be lower margins because of pres-
sure on premiums. In fact, the traditional business
model of US health insurers is increasingly coming
into question with the rise of accountable care organi-
zations (ACOs). The net result is that the expansion in
worldwide insurance coverage will come largely from
emerging markets, with growth in Europe remaining
fairly stagnant.
Providers of care worldwide will see the largest volume
gains, but not necessarily any increase in their overall
margins. These volume increases will drive 30% of the
overall profit pool growth (about $70 billion), but prof-
itability will be flat or will decline. In fact, the overall
profitability of healthcare players is expected to decrease
by about 1% by 2020.8
The slower growth in US and European markets will be
offset to some degree by expansion in emerging markets
like China and India, specifically for generic drug
products. Rapid economic growth and the rise of chronic
diseases will produce substantial gains for price-sensitive
generic products, but weak medical insurance and gaps
in delivery capability in rural areas will remain chal-
lenges for these economies.
China’s healthcare profit pool will grow from about
$22 billion in 2010 to $113 billion in 2020, a CAGR of
18%,9
suggesting appealing opportunities for new
investments, but hospitals and other providers will drive
40% of that growth (see Figure 2).10
Those providers
will benefit from an aging population and a rising
middle class, and there are also some signs of govern-
ment policies that are favorable to private investment
in the sector. Pharmaceutical and medical technology
companies will continue to realize attractive earnings
before interest and tax (EBIT), but brand, generic and
over-the-counter products will shrink by one percentage
point because of government-enforced price cuts and
the increasing purchasing power of distributors.
Likewise, in India, the delivery of care and pharma-
ceutical sales will make up most of the fragmented
$65 billion market.11
Disruptive changes will alter the basis of com-
petition, creating new opportunities to redefine
business models and enter new markets
The sheer size of emerging markets makes them attrac-
tive offsets to more stagnant growth in other regions of
the world. But to be successful, companies will need new
business models to take advantage of the opportunities
there (see Figure 3). Profit pool shifts and the lack of
access to healthcare in many countries, for example,
may spur some pharmaceutical and medical technology
companies to meet the challenge by opening clinics
in the developing world, or even entering the private
insurance market.
In the developed world, providers and payers are already
entering the device or drug market. Companies like
Fresenius Medical Care, which started out producing
dialysis machines, have emerged to “own” an entire
segment of care—vertically integrated with machines,
clinics and drugs. With global government spending
estimated at about $50 billion for dialysis products and
services, but with shrinking reimbursement per treat-
ment, the vertically integrated model may be an effective
path to capture a very specific part of the profit pool.12
6. 4
Healthcare 2020
Figure 3: Industry changes will create opportunities to redefine business models and enter new markets
Global markets
Consumer driven demand Professionalization of care
• Co development with consumers
• Home healthcare and tele healthcare
• Patient journey treatment experience
• Personal care platforms
• Nutrition and wellness solutions
• Personalized devices
Individual engagement
and experience
• Own disease protocols
• “Sell outcomes”
• Integrated care (Rx, Dx, home, etc.)
• Risk sharing with Rx, Dx, device,
providers, payers, employers
• Value solutions
Healthcare population solutions
Profit pool
driver
Implications
and
opportunities
Source: Bain & Company, Inc.
Figure 2: Hospitals and other providers account for about 40% of China’s profit pool growth
Note: OTC includes ~60% health nutrition; other providers include outpatient services, clinics and specialist services such as obstetrics and pediatrics
Sources: IMS; BMI; Espicom; annual reports; analyst reports; China Health Yearbook; National Bureau of Statistics of China; Bain analysis
0
25
50
75
100
$125B
2010
22
2020
113
17.6%
China healthcare profit pool growth 2010–2020 (USD)
CAGR
(10–20)
40% of profit
pool growth
28
Hospital
9
Other
providers
17
Pharma
Gx
6
Pharma
OTC
6
Pharma
Rx
13
Medtech
7
Distribution
2
Retail
pharmacy
1
CXO
1
Insurance
7. Healthcare 2020
5
While the specificities differ by market, the overall
trend is that companies are seeking incremental growth
in new profit pools that tie to disease knowledge or
market know-how.
On what basis will you compete? If you can no longer
depend only on increased volume or control pricing,
where can you most profitably operate in the newly
configured global market? This is where the acceleration
of twin trends—consumer-driven demand and stan-
dardized and protocolized care—comes into play. These
two trends are powerful and have the capacity to facili-
tate the shift to outputs over inputs, stimulating new
opportunities for profitable growth, if you can adapt
your business model.
• With more information about treatments available
to an increasing number of consumers or patients
around the globe, every company with a product to
sell must understand how best to engage with con-
sumers, in a way that speaks to their individual
needs and patient experience. Search engines have
produced a vast engaged patient population we
could not have imagined even 10 years ago: 80%
of Internet users now search for health information
online, and more than half look for specific infor-
mation about a medical treatment or disease.13
The demand for more engagement is not limited
only to the US and Europe. Mobile phones and
Internet access are now available in most emerging
economies. While there will continue to be cultural
differences in the way consumers engage with their
care, the degree of engagement itself will only inten-
sify globally. More than one-third of Indians, for
example, currently use the Internet to search for
health information, with similar percentages of
younger, more educated people seeking health
information online in Brazil, Mexico and China.14
• Along with the trend toward increased consumer
engagement is an increasing professionalization of
medical care processes. We call this trend proto-
colization because physicians and other providers
are accepting and using more standardized proto-
cols and guidelines for treating their patients. US
providers have been somewhat slower to embrace
clinical protocols than their European or Asian
counterparts, but there is little doubt about the
direction of this change. No longer will the indi-
vidual physician be the lone decision maker. The
cottage industry of medical care is being industri-
alized, as payers and providers increasingly align
their businesses—and results—which may be
threatening to some, but may well produce better
care at lower cost.
Protocolization and consumerism will not
affect all therapeutic areas equally
There are at least four “landscapes” where healthcare
companies will have to make strategic decisions in
order to survive and win (see Figure 4).15
On one axis of Figure 4, we included the conditions and
diseases for which consumer engagement will be the
main market driver; on the other, we have shown the
degree to which standard protocol will guide treatment
decisions. In some areas of treatment, both consumer
engagement and protocolization will be in play, lead-
ing to an opportunity for patient-provider “teaming.”
Both of these trends translate into reduced autonomy
and decision-making control for physicians for estab-
lished conditions.
Where there is a high degree of consumer engagement
but low protocolization, the patient experience will
impact the outcomes most strongly. Such treatment
options are often cash-based or lifestyle therapies, like
breast implants or erectile dysfunction. Brands will
initially rule for these types of procedures because of
their familiarity and marketing clout, but prices may be
forced down over time as the experience curve is applied
to these markets. The degree of protocolization for
these therapies will start out weak, but will increase
with competition, especially for treating conditions
like infertility, where buyers perceive proprietary pro-
tocols to be an advantage.
The more routine, protocol-driven therapies, such as for
conditions like hypertension or procedures for knee or
hip replacement, involve processes of care that are
generally well accepted, but result in less physician
discretion and patient choice. Manufacturers of products
for these conditions will need to have good data to
accurately price their products and ensure that they are
8. 6
Healthcare 2020
growth in those types of markets. Therapies for migraines
or attention deficit hyperactivity disorder (ADHD), for
example, have fewer accepted protocols, and thus payers
will continue to struggle to control utilization beyond
mere cost shifting. New physician-driven therapies will,
of course, continue to emerge, but the overall trend is
clearly away from full physician control as markets
mature and consumers become more involved in their
own healthcare.
Over time, more diseases will move up and to the right-
hand side of Figure 4. Protocolization and consumerism
will increase, and payers will demand and use better
data about outcomes. Although these changes will not
guarantee increased revenue, good outcomes should
result in a better share of the profit pool for players that
can shape the protocol development by demonstrating
how their products create value.
Where can you play—and win—by 2020?
Only transformational business models will enable future
winners to capitalize on the disruptive market changes
included in any protocols being developed to guide
treatment. Whatever patient marketing exists for these
types of conditions will largely focus on adherence because
care management, not just the specific product, results
in better outcomes.
Where there is a high degree of consumer engagement
along with a high degree of protocolization for diseases
like breast cancer or Type 1 diabetes, manufacturers
will need to be sure that they shape the protocols being
used and target their marketing to those preferred ther-
apeutic options. The “teaming” between providers and
patients will be a significant challenge for payers and
manufacturers. In the area of breast cancer alone, the
existence of multiple effective patient advocacy organi-
zations will inform patients of their options, and they
in turn will put pressure on doctors to find the optimal
treatment regimen. Payers will attempt to control the pro-
tocol development in this area in order to control costs.
The physician-driven quadrant, with its lower degree of
consumer engagement and protocolization, is a “busi-
ness as usual” state, and there is unlikely to be significant
Figure 4: Trends affect disease states and procedures differently, creating distinct market dynamics
Protocolization
Note: We determined the placement of diseases or conditions in this figure by assessing the number of protocols available, adjusted for prevalence and total spending on that condition.
For consumerization, we measured online presence and also adjusted for prevalence
Sources: International Guideline Library; National Guideline Clearinghouse data; National Health Service (UK); Medtech Insight; Bain analysis
Dialysis
Patient
engagement
Breast implants
(aesthetics)
T1 Diabetes
Breast cancer
Hernia
Erectile
dysfunction
Pharma
Medtech
Consumer driven Patient and provider teaming
Protocol driven
Infertility
Lupus
Liver
cancer
Physician driven
Asthma
Depression
Contraception
ADHD
Hypertension
Migraine
Gastric band
Stents
RA
ICD/Pacemaker
HIV T2 Diabetes
MS
Schizophrenia
Asthma
Alzheimer’s
Osteoporosis
Knee/Hip
replacement
9. Healthcare 2020
7
at play (see Figure 5). The models identified in Figure 5
are very different from the business models being dis-
cussed in boardrooms today. Becoming a consumer
marketing powerhouse, a disease population manager
or a successful integrated care company will require
different organizational capabilities. For example, for
treatments and conditions where the degree of consumer
demand is high, like health and wellness programs, or
for treatments with high brand recognition, a consumer
powerhouse approach can help produce differential
growth and market share. For conditions with a high
degree of protocolization like hypertension, a popula-
tion-manager approach may be the answer. The most
challenging model of all will be to create integrated
care solutions that manage the full suite of products
and services across the patient journey. This approach
will require deep expertise in patient-centered care and
the tools that support that care, such as real-time feed-
back, secure communication and digital technology to
enhance patient participation.
These new approaches require a fresh look across the
profit pool for each condition. Here are a few examples
to think about:
• For businesses in the more traditional, physician-
dominated quadrants of Figure 4, winners will
build the capabilities to deliver risk-sharing models,
potentially partnering with payers and providers—
or even directly becoming more involved in the
delivery of care.
• If you are operating in the top right-hand quadrant
of Figure 4, patient-provider teaming, then you may
need to partner or develop capabilities in data
sharing and coordination to ”wrap around” the
patient and manage a population for a payer or
provider organization.
• If you operate more in the consumer world, you may
need to move beyond branding the product and
start branding the procedure by forming alliances
with certified providers that can perform the pro-
cedure or provide medication, such as exclusive,
branded and certified botulinum toxin clinics.
Figure 5: Transformational models hope to capitalize on expected market changes
Profit pool driver
DescriptionConsumer driven
demand
Professional
ization of care
Model
• Consumer driven health and wellness programs
– Products for full economic spectrum
• Consumer engagement to drive brand awareness and loyalty
• Innovation oriented to consumer wants (beyond medical needs)
– Global consumer insight and brand building skills
• Focus on managing disease in populations
– Facilitate access, compliance, outcomes, systems cost reduction
• Partner as necessary to influence stakeholders across the continuum of care
• Leader in science, protocols, global care norms
– Epidemiology, policy, education, behaviors, actuarial
• Integrated care management throughout the patient journey
– “Closed” system to facilitate the full physician and patient experience
• Full suite of products and services to deliver all aspects of the patient journey
• Deep expertise in patient centric experiences and tools
– Patient insight, self directed disease management tools, social networks
– Secure communication, compliance 2.0, real time feedback, etc.
• Ability to link patient experiences to outcomes
– Clinical and actuarial data, risk management tools
Consumer
marketing
powerhouse
Disease
population
manager
Integrated
care
company
Source: Bain & Company, Inc.
10. 8
Healthcare 2020
ways to reduce cost and demonstrate improved qual-
ity. For providers, it will be a choice of joining the
rush to become an integrated care company or trying
to find room to be a branded provider of choice.
For a select few, the old models could work—break-
through innovation will still drive profitable growth,
but few, if any, have proven the ability to sustain this
over time. Cost pressures will force nearly every company
in the industry to rethink how and where it will grow
moving forward. Good strategic choices will still yield
growth. A profit pool that is growing at a breakneck
pace will no longer shelter poor choices. Executives
and investors can and must know where the profit
pools are shifting—and how they will change course
to successfully compete.
• Where the various components of the profit pool
have created silos, with products and patients being
passed around among them, the trend toward pro-
tocolization and consumerization will break down
barriers and create a more integrated approach for
a given medical condition or procedure. Firms like
Fresenius and DaVita are already doing this, and other
healthcare companies will either participate in this
trend or risk becoming mere commodity suppliers.
• The industry’s metrics will need to change. Using
annual budgets and per person savings will not reflect
value adequately for either private or government
payers. Can payers stay involved for long-term gain
when paying for chronic diseases? Public payers
may not be able to resist the pressures to simply
reduce their costs. Private payers will need to identify
1 IMS Institute for Healthcare Informatics, “The Global Use of Medicines: Outlook Through 2015,” May 2011.
2 The methodology Bain used for developing this profit pool analysis is based on detailed health sector revenue and EBIT margin analysis for US and global sectors. The sector revenues
are based and triangulated on latest market reports; the sector margins are based on company annual reports; the 2010-2020 CAGRs are based on market reports, where available, and
Bain estimates; and the margin changes from 2010 to 2020 are based on proprietary Bain analysis.
3 The term “protocolization” refers to the application of proven standards of care and consistent protocols and guidelines to reduce variation in the delivery of healthcare.
4 Sources: Bain analysis, IMS, Datamonitor, Business Insights, Freedonia, annual reports, analyst reports, Centers for Medicare and Medicaid Services (CMS), OECD
5 Sources: Datamonitor; based on top 50 branded pharma companies
6 Sources: Business Insights, Datamonitor, analyst reports, Bain analysis
7 Sources: Business Insights, Datamonitor, Parexel, analyst reports, Bain analysis
8 Sources: IMS, Datamonitor, Business Insights, Freedonia, annual reports, analyst reports, CMS, OECD, Bain analysis
9 Sources: IMS, BMI, Espicom, annual reports, analyst reports, China Health Yearbook, National Bureau of Statistics of China, Bain analysis
10 Sources: IMS, BMI, Espicom, annual reports, analyst reports, China Health Yearbook, National Bureau of Statistics of China, Bain analysis
11 Source: Bain analysis
12 Fresenius Medical Care, “Forward Looking Statements,” 2009, p.31.
13 Susannah Fox, Pew Research Center’s Internet & American Life Project – Health Topics, February 1, 2011, http://pewinternet.org/Reports/2011/HealthTopics.aspx.
14 “Indians Increasingly Use Internet for Their Healthcare Needs,” Express Healthcare, http://www.expresshealthcare.in/201201/theyearthatwas201152.shtml.
15 Sources: International Guideline Library, National Guideline Clearinghouse data, National Health Service in UK, Medtech Insight and proprietary Bain analysis
The methodology for determining the degree of consumer engagement and protocolization in Figure 4 was developed by collecting all the protocols on each disease from a variety
of sources, scoring the current level of protocolization on a scale of one to 10 and then adjusting for prevalence and total spending on the disease. For consumerism, we monitored
the presence of topics for each disease on a variety of patient websites and corrected for prevalence.
11. Shared Ambition,True Results
Bain & Company is the management consulting firm that the world’s business leaders come
to when they want results.
Bain advises clients on strategy, operations, technology, organization, private equity and mergers and acquisitions.
We develop practical, customized insights that clients act on and transfer skills that make change stick. Founded
in 1973, Bain has 48 offices in 31 countries, and our deep expertise and client roster cross every industry and
economic sector. Our clients have outperformed the stock market 4 to 1.
What sets us apart
We believe a consulting firm should be more than an adviser. So we put ourselves in our clients’ shoes, selling
outcomes, not projects. We align our incentives with our clients’ by linking our fees to their results and collaborate
to unlock the full potential of their business. Our Results Delivery®
process builds our clients’ capabilities, and
our True North values mean we do the right thing for our clients, people and communities—always.